Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BioDrain Medical Inc. Signs Additional Independent Distribution Agreements, Strengthening Nationwide Presence View HTML
Toggle Summary BioDrain Medical Lands Key Accounts In Minnesota And Michigan Expanding Its U.S. Market Share
Installation completed at an AAAHC (Accreditation Association for Ambulatory Health Care, Inc.) certified Surgical Center in Pennsylvania.
View HTML
Toggle Summary BioDrain Medical Retains KCSA Strategic Communications as Corporate Communications Counsel View HTML
Toggle Summary BioDrain Medical, Inc. Announces Company Name Change to Skyline Medical Inc.
Company Will Now Trade Under New Ticker "SKLN"
View HTML
Toggle Summary BioDrain Medical, Inc. Implements Initiatives to Position Itself for Sustained Growth View HTML
Toggle Summary CORRECTING and REPLACING - Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
In a release issued under the same headline earlier today by Precision Therapeautics (NASDAQ:AIPT), please note that the forward-looking statements paragraph was missing. The corrected release follows: MINNEAPOLIS , April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc.
View HTML
Toggle Summary Dr. Bob Murphy, Head of Computational Biology at Carnegie Mellon University, Joins Precision Therapeutics’ Scientific Advisory Board
MINNEAPOLIS , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Robert Murphy to its Scientific Advisory Board . Dr.
View HTML
Toggle Summary Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966
Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine
View HTML
Toggle Summary Helomics® Corporation and Ariel Precision Medicine, Inc. sign a services agreement to Advance Clinical Genomics in Precision Medicine Applications
PITTSBURGH , Dec. 20, 2017 (GLOBE NEWSWIRE) -- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and Ariel Precision Medicine, Inc.
View HTML
Toggle Summary Helomics® Corporation Announces the appointment of Dr. Marc Malandro to its Advisory Board, providing strategic insights for the Skyline Medical – Helomics Joint Venture
PITTSBURGH , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the addition of Marc Malandro PhD, CLP, RTTP,
View HTML